Latest / The Well-Built Life / Leukemia
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. So, let's dive into the complexities
- 0:26Speaker 1: of leukemia. It's surprising how much we have learned about
- 0:30Speaker 1: this disease over the years, from ancient origins to today's
- 0:33Speaker 1: sophisticated treatments. Thomas, can you start by giving us a
- 0:38Speaker 1: brief overview of how our understanding of leukemia has evolved?
- 0:41Speaker 2: Certainly, Rachel. The historical timeline is fascinating. The earliest mentions
- 0:46Speaker 2: of cancer can be traced back to ancient medical texts,
- 0:50Speaker 2: but serious scientific study didn't hit its stride until the
- 0:53Speaker 2: late 19th century. By the 1950s, leukemia was classified into
- 0:59Speaker 2: acute and chronic subtypes, which was a big step forward.
- 1:02Speaker 2: Bone marrow transplantation came into play in the 1960s, completely
- 1:08Speaker 2: transforming survival rates.
- 1:10Speaker 1: Right, and that's the crucial nuance here. The 1960s and
- 1:15Speaker 1: 70s were transformative, with the introduction of bone marrow transplantation
- 1:20Speaker 1: as a viable treatment option. It's a testament to how
- 1:23Speaker 1: quickly medical science can evolve when faced with a daunting challenge.
- 1:27Speaker 2: Exactly, which brings up an interesting contradiction. While bone marrow
- 1:31Speaker 2: transplants were revolutionary, they are still incredibly risky and not
- 1:36Speaker 2: always accessible. It's a stark reminder of the disparity in
- 1:39Speaker 2: medical treatments globally.
- 1:41Speaker 1: Definitely, and that segues nicely into the 1980s and 90s.
- 1:47Speaker 1: During this period, targeted therapies and chemotherapy modifications began to
- 1:52Speaker 1: rise to the surface, particularly for chronic myeloid leukemia, CML.
- 1:57Speaker 1: The development of tyrosine kinase inhibitors, like Gleevec, marked a
- 2:01Speaker 1: paradigm shift in CML management.
- 2:04Speaker 2: Wait, but how does that actually play out in practice?
- 2:08Speaker 2: Gleevec has been a game changer, but it's also an
- 2:11Speaker 2: expensive drug. I often hear from patients who can't afford it,
- 2:15Speaker 2: which brings us to the broader issue of access and affordability.
- 2:18Speaker 1: That brings us to an important point, Thomas. We can't
- 2:22Speaker 1: just focus on the fancy new treatments without considering the
- 2:26Speaker 1: real-world impact on patients. The 2000s saw a wave of
- 2:31Speaker 1: precision medicine and immunotherapy, which have certainly improved outcomes. But
- 2:36Speaker 1: those advancements come at a cost.
- 2:38Speaker 2: And it's not just the cost, Rachel. The current decade
- 2:42Speaker 2: has seen amazing strides with advancements like CAR-T cell therapy.
- 2:47Speaker 2: But what about the logistics? How does a patient even
- 2:50Speaker 2: get access to these cutting-edge treatments? It's a complex web
- 2:54Speaker 2: of healthcare systems and bureaucratic red tape.
- 2:56Speaker 1: Absolutely. The future outlook in leukemia treatment is exciting. But
- 3:01Speaker 1: the reality is that we still have a long way
- 3:03Speaker 1: to go. Artificial intelligence and machine learning are poised to
- 3:06Speaker 1: revolutionize diagnostics and treatment processes. But we need to ensure
- 3:10Speaker 1: these tools benefit every patient, not just those with access.
- 3:14Speaker 2: Exactly. And let's not forget the ethical considerations. Using genetic
- 3:19Speaker 2: testing and targeted therapies raises questions about patient consent and
- 3:23Speaker 2: the potential for misuse. We need a holistic approach that
- 3:27Speaker 2: addresses these issues.
- 3:28Speaker 1: Well said. As we wrap up this section, let's make
- 3:32Speaker 1: sure to highlight the importance of continued research and innovation
- 3:36Speaker 1: in leukemia treatment. We have come a long way, but
- 3:39Speaker 1: there is still so much work to be done. So,
- 3:43Speaker 1: let's dive into some of the key mechanisms at play here. Thomas,
- 3:47Speaker 1: can you explain what cell proliferation in leukemia means? How
- 3:52Speaker 1: exactly do these abnormal cells take over the bone marrow?
- 3:55Speaker 2: Sure, Rachel. Cell proliferation in leukemia is a process where
- 4:00Speaker 2: hematopoietic cells divide and multiply uncontrollably. It's like the body
- 4:06Speaker 2: is stuck in a hyperactive growth mode where these cells
- 4:08Speaker 2: keep multiplying, crowding out the space for healthy cells. This
- 4:12Speaker 2: affects the production of all blood cells, red blood cells,
- 4:16Speaker 2: white blood cells, and platelets.
- 4:19Speaker 1: Right. And that's the crucial nuance here. How do these
- 4:22Speaker 1: cells manage to hijack the normal growth cycle? Are there
- 4:26Speaker 1: specific genetic alterations involved in this process?
- 4:30Speaker 2: Exactly, which brings up an interesting contradiction. There are specific
- 4:34Speaker 2: chromosomal translocations and gene mutations that can trigger this abnormal growth.
- 4:39Speaker 2: One classic example is the Philadelphia chromosome. which causes CML,
- 4:44Speaker 2: these genetic changes essentially switch on certain genes, leading to
- 4:48Speaker 2: uncontrolled cell division. It's fascinating how a tiny change in
- 4:52Speaker 2: the DNA can have such massive repercussions.
- 4:55Speaker 1: That's wild when you look at the raw numbers. Let's
- 4:58Speaker 1: talk about the impact of these genetic alterations. Can you
- 5:02Speaker 1: explain how these changes disrupt normal cell differentiation?
- 5:05Speaker 2: Certainly. During normal development, Cells go through a series of
- 5:10Speaker 2: steps where they decide whether to become red blood cells,
- 5:13Speaker 2: white blood cells, or platelets. In leukemia, this process gets
- 5:18Speaker 2: messed up. The cells end up stuck in a state
- 5:21Speaker 2: where they can't fully develop into functional blood cells. This
- 5:24Speaker 2: leads to a buildup of these abnormal, non-functional cells, which
- 5:29Speaker 2: is why patients often suffer from symptoms like anemia and immunodeficiency.
- 5:34Speaker 1: Speaking of which, How do these mechanisms translate into clinical
- 5:37Speaker 1: symptoms for patients? Are certain symptoms more indicative of one
- 5:42Speaker 1: type of leukemia over another?
- 5:44Speaker 2: Each type of leukemia has its own distinct set of symptoms.
- 5:48Speaker 2: For instance, acute lymphoblastic leukemia. All often presents with fatigue, fever,
- 5:55Speaker 2: and easy bruising due to a lack of healthy white
- 5:58Speaker 2: blood cells. Acute myeloid leukemia, AML. can lead to more
- 6:02Speaker 2: severe symptoms like bone pain and frequent infections. The challenge
- 6:07Speaker 2: is that these symptoms can overlap, making it difficult to
- 6:10Speaker 2: diagnose early without genetic testing.
- 6:13Speaker 1: Absolutely. And let's not forget the role of healthcare providers
- 6:17Speaker 1: in diagnosing and treating these conditions. How do they navigate
- 6:22Speaker 1: the complexity of these diagnoses?
- 6:24Speaker 2: Healthcare providers are really the linchpin here. They have to
- 6:28Speaker 2: be vigilant for signs of leukemia and rule out other
- 6:31Speaker 2: conditions that might cause similar symptoms. The ABT assessment is
- 6:35Speaker 2: a standard tool for quick triage and determining if a
- 6:38Speaker 2: patient needs further workup. It's a stark reminder of the
- 6:42Speaker 2: importance of early detection and the burden on healthcare providers
- 6:46Speaker 2: to stay current with the latest diagnostic tools and treatments.
- 6:50Speaker 1: So, we have talked about the complexities of the diagnosis
- 6:53Speaker 1: and treatment. But let's zoom in on the nitty-gritty of
- 6:56Speaker 1: what's happening at the cellular level, specifically how genetic testing
- 7:01Speaker 1: and immune responses intertwine. Thomas, how do we navigate the
- 7:05Speaker 1: contradictions when it comes to diagnosing leukemia?
- 7:08Speaker 2: Right, and that's the crucial nuance here. Genetic testing is
- 7:12Speaker 2: a powerful tool, but it's not a one-size-fits-all solution. Take,
- 7:17Speaker 2: for example, the distinction between acute myeloid leukemia and AML
- 7:22Speaker 2: and acute lymphoblastic leukemia. Both can present similarly, making initial
- 7:28Speaker 2: diagnosis tricky. The presence of specific chromosomal abnormalities like the
- 7:33Speaker 2: Philadelphia chromosome in CML can direct us to targeted therapies.
- 7:38Speaker 2: But what if we have a case that doesn't fit
- 7:41Speaker 2: neatly into any category? How do we proceed then?
- 7:44Speaker 1: That's a great point. It's like trying to fit a
- 7:47Speaker 1: square peg into a round hole. And we can't forget
- 7:50Speaker 1: the role of immune responses. Some patients might have robust
- 7:53Speaker 1: immune systems that fight off infections effectively, but when faced
- 7:57Speaker 1: with leukemia, this same system can become overwhelmed and lead
- 8:01Speaker 1: to immunosuppression, making them susceptible to other infections. It's a
- 8:06Speaker 1: delicate balance.
- 8:07Speaker 2: Exactly, which brings up an interesting contradiction. On one hand,
- 8:12Speaker 2: we are using immune-based therapies to fight leukemia, which in
- 8:16Speaker 2: theory should help enhance the patient's natural defense mechanisms. But
- 8:21Speaker 2: on the other hand, these therapies can sometimes push the
- 8:24Speaker 2: system too far, leading to a temporary state of immunosuppression
- 8:28Speaker 2: where the patient becomes more vulnerable.
- 8:30Speaker 1: That's wild when you look at the raw numbers. For instance,
- 8:33Speaker 1: the incidence of fungal infections in leukemia patients undergoing intensive
- 8:37Speaker 1: chemotherapy can be as high as 30%, despite the fact
- 8:42Speaker 1: that these patients are on antifungal prophylaxis. It's a real challenge,
- 8:47Speaker 1: and let's not forget the impact on quality of life.
- 8:50Speaker 1: Patients might be on such a cocktail of medications and
- 8:54Speaker 1: treatments that it just takes a toll from the side
- 8:57Speaker 1: effects to the physical and emotional strain.
- 9:00Speaker 2: Right. And that brings us to the ethical considerations too.
- 9:05Speaker 2: We are walking a fine line between giving patients the
- 9:08Speaker 2: best possible treatment and ensuring they maintain a good quality
- 9:12Speaker 2: of life. It's tough, but it's crucial for us to
- 9:15Speaker 2: keep that in mind. We need to find that sweet spot,
- 9:18Speaker 2: if you will. where the treatment is effective but not
- 9:21Speaker 2: overly harsh.
- 9:22Speaker 1: Absolutely. And it's not just about the patients. Healthcare providers
- 9:26Speaker 1: also face a tough challenge here. They have to juggle
- 9:29Speaker 1: the need for aggressive treatments with the need to protect
- 9:31Speaker 1: patients from side effects. It's a constant balancing act, and
- 9:35Speaker 1: there are no easy answers. But that just makes it
- 9:38Speaker 1: all the more important to have these conversations and keep
- 9:41Speaker 1: pushing for advancements in this field. As we move forward,
- 9:44Speaker 1: let's delve into the challenges and future outlook. One of
- 9:48Speaker 1: the major issues in diagnosing leukemia is the overlap and
- 9:52Speaker 1: similarity between subtypes, like acute myeloid leukemia, AML, and acute
- 9:57Speaker 1: lymphoblastic leukemia. All, Thomas, can you elaborate on why this
- 10:02Speaker 1: is such a problem?
- 10:03Speaker 2: Absolutely, Rachel. The complexity stems from the fact that the
- 10:07Speaker 2: initial symptoms can be quite similar, making it hard to
- 10:10Speaker 2: distinguish between the two types of leukemia, especially at the
- 10:14Speaker 2: early stages. For instance … If a patient presents with fever,
- 10:18Speaker 2: weight loss, and fatigue, you can't immediately tell whether it's
- 10:22Speaker 2: AML or all without further diagnostic testing. This is where
- 10:26Speaker 2: genetic testing plays a crucial role, but it's not always straightforward.
- 10:30Speaker 1: That's a tricky issue, and it underscores the need for
- 10:33Speaker 1: more accurate diagnostic tools. Speaking of which, how do you
- 10:38Speaker 1: see AI-assisted diagnostics shaping the future of leukemia diagnosis? With
- 10:43Speaker 1: the advancements in machine learning, Could we actually improve the
- 10:47Speaker 1: initial screening processes?
- 10:49Speaker 2: AI could indeed revolutionize preliminary screening by analyzing vast amounts
- 10:53Speaker 2: of data to identify patterns and anomalies that might be
- 10:56Speaker 2: missed by human eyes. For example, AI could enhance the
- 11:00Speaker 2: accuracy of bone marrow cytology images, helping to detect subtle
- 11:04Speaker 2: changes that might indicate an earlier stage of leukemia. However,
- 11:08Speaker 2: the key will be in ensuring the AI systems are
- 11:11Speaker 2: trained on diverse and representative datasets to avoid bias and
- 11:15Speaker 2: improve overall reliability.
- 11:17Speaker 1: That's a great point about avoiding bias. Now, let's turn
- 11:21Speaker 1: to treatment. We have seen significant advancements in targeted therapies,
- 11:26Speaker 1: but Therese, still a lot of room for improvement. How
- 11:30Speaker 1: do you envision combination therapies playing a part in the future?
- 11:33Speaker 2: Combination therapies are crucial because no single treatment is perfect
- 11:38Speaker 2: for every patient. For instance, in chronic myeloid leukemia, CML,
- 11:43Speaker 2: we have seen how tyrosine kinase inhibitors have transformed the landscape.
- 11:48Speaker 2: But for other subtypes, like AML, combining these targeted therapies
- 11:53Speaker 2: with chemotherapy could potentially offer a more robust treatment option.
- 11:58Speaker 2: The goal would be to tailor the treatment to the
- 12:00Speaker 2: unique characteristics of each patient's case, which is where personalized
- 12:05Speaker 2: medicine comes in.
- 12:06Speaker 1: Indeed, personalized medicine is key. It's about moving away from
- 12:11Speaker 1: a one-size-fits-all approach to something that's more adaptable to the
- 12:15Speaker 1: individual needs of the patient. How close do you think
- 12:18Speaker 1: we are to achieving that level of customization?
- 12:21Speaker 2: We are getting closer, but there are still hurdles to overcome.
- 12:25Speaker 2: One of the biggest challenges is the sheer complexity of
- 12:28Speaker 2: genetic alterations in leukemia cells. Each mutation could require a
- 12:33Speaker 2: different treatment strategy. However, advances in genetic sequencing and bioinformatics
- 12:39Speaker 2: are making it more feasible to design personalized treatment plans.
- 12:44Speaker 2: The next step could involve integrating real-time data from wearable
- 12:48Speaker 2: devices and other health metrics to dynamically adjust treatment. based
- 12:52Speaker 2: on the patient's response.
- 12:54Speaker 1: It sounds exciting, but also quite daunting. One final question.
- 12:59Speaker 1: How do you see AI and machine learning assisting in
- 13:01Speaker 1: optimizing and streamlining treatment processes for leukemia patients?
- 13:06Speaker 2: AI could play a vital role in optimizing treatment pathways
- 13:10Speaker 2: by predicting patient responses to different therapies. This could save
- 13:14Speaker 2: time and resources by personalizing treatment from the start, potentially
- 13:19Speaker 2: reducing the trial and error phase. Additionally, AI could help
- 13:23Speaker 2: manage complex treatment regimens, ensuring that all necessary protocols are
- 13:27Speaker 2: followed consistently. The ultimate goal is to improve outcomes while
- 13:31Speaker 2: minimizing the burden on healthcare providers and patients.
- 13:35Speaker 1: As we wrap up today's episode, let's explore the broader
- 13:38Speaker 1: strategic landscape. How might the rapid advancements in leukemia research
- 13:43Speaker 1: and treatment impact the industry at large?
- 13:46Speaker 2: Thomas. Great question, Rachel. Ethical considerations loom large. Take, for example,
- 13:52Speaker 2: the use of genomics and personalized medicine. While these approaches
- 13:56Speaker 2: offer tailored treatments, they also raise questions about data privacy
- 14:01Speaker 2: and consent, especially given the sensitive nature of genetic information.
- 14:05Speaker 1: Exactly. And these ethical challenges extend beyond just the patients.
- 14:10Speaker 1: They affect how healthcare providers and pharmaceutical companies approach data
- 14:14Speaker 1: sharing and research collaborations. This ethical landscape is not just
- 14:18Speaker 1: about technology. but also about trust within the medical community.
- 14:22Speaker 2: Absolutely. And let's not forget the global disparities. In resource-limited settings,
- 14:28Speaker 2: the gap between advanced treatment options in developed countries and
- 14:31Speaker 2: the realities faced by many patients can be stark. Countries
- 14:35Speaker 2: like India or many sub-Saharan African nations struggle to access
- 14:39Speaker 2: the cutting-edge therapies that are standard in wealthier nations.
- 14:42Speaker 1: That's wild when you look at the raw numbers. In
- 14:45Speaker 1: some regions, the survival rates for leukemia are significantly lower
- 14:49Speaker 1: due to these access issues. It brings up the importance
- 14:52Speaker 1: of global cooperation and funding to bridge this gap.
- 14:55Speaker 2: Exactly. It's not just a matter of handing out treatments.
- 14:59Speaker 2: It's about ensuring that the necessary infrastructure and support systems
- 15:03Speaker 2: are in place. That's where initiatives like the Global Oncology
- 15:07Speaker 2: Initiative come in. They are striving to create more equitable
- 15:11Speaker 2: access to diagnosis and treatment.
- 15:13Speaker 1: Right. And speaking of infrastructure, the integration of AI and
- 15:17Speaker 1: machine learning in leukemia diagnosis and treatment could have a
- 15:21Speaker 1: profound impact. These technologies can streamline processes, but they also
- 15:27Speaker 1: require robust support and training for healthcare professionals. It's a
- 15:31Speaker 1: balancing act.
- 15:32Speaker 2: True, and the future of leukemia research will likely be
- 15:35Speaker 2: driven by these technological advances. However, we need to ensure
- 15:40Speaker 2: that these tools are deployed responsibly and ethically. For instance,
- 15:44Speaker 2: the use of AI in decision-making should always consider the
- 15:47Speaker 2: human element and not replace the judgment of clinicians entirely.
- 15:51Speaker 1: That's a crucial point. The future of leukemia treatment involves
- 15:55Speaker 1: personalization and precision. But we must also foster global collaboration
- 16:00Speaker 1: to ensure that these advancements benefit everyone, not just those
- 16:03Speaker 1: in certain parts of the world. We can't let disparities
- 16:06Speaker 1: widen as we move forward.
- 16:08Speaker 2: Absolutely. It's a complex web, but one we are well-equipped
- 16:12Speaker 2: to navigate if we approach it with a commitment to collaboration, ethics,
- 16:16Speaker 2: and equitable access. Let's keep pushing for progress, but do
- 16:20Speaker 2: so with a mindful and compassionate eye.
- 16:22Speaker 1: That brings us to the end of today's episode. Thank
- 16:25Speaker 1: you so much for spending part of your day with me.
- 16:28Speaker 1: If you found this episode's tips helpful and want to
- 16:31Speaker 1: make sure you don't miss the next conversation, please take
- 16:34Speaker 1: a quick second to hit that subscribe button. or follow
- 16:37Speaker 1: button on whatever platform you are listening on. It's a
- 16:40Speaker 1: completely free way to support the show and helps more
- 16:43Speaker 1: people find us. This podcast is independently produced, so if
- 16:47Speaker 1: you are ever in a position where you would like
- 16:49Speaker 1: to help keep it running, we do accept small donations.
- 16:53Speaker 1: You can find a link right in the episode description
- 16:55Speaker 1: below to buy us a coffee or contribute what you can.
- 16:58Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 17:03Speaker 1: and we will talk again soon.